Latest Content

A pharma expert and clinician shares perspectives on developing treatments.

“Each person the right to tell their own story in their own way”: An Italian-Canadian psychiatrist traces family journeys across 3 countries, revealing migration’s lessons on identity, belonging, and resilience.

Exercise boosts recovery in depression and psychosis, and improves cognition and quality of life; clinicians can now use the 5A model to make movement a routine psychiatric tool.

Artemis II astronauts spark a psychiatrist’s look at “joy trains,” music, and meaning—practical ways teams rekindle joy and prevent burnout.

Reality TV puts therapy on camera, reducing stigma but raising ethical, privacy, and misinformation risks—and affecting viewers and cast.

New ASAM youth criteria redefine SUD care with brain-stage levels, chronic monitoring, detox safety, and family-centered support.

From Artemis II’s fiery return to life after prison or vacation, this article shows how reentry stress becomes a skill for growth.

To prescribe or not to prescribe?

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

A new US Department of War backed phase 2a study will test BXCL501's efficacy in easing acute stress reactions and preventing PTSD.

Stroke recovery lasts years; learn why fatigue, sleep, hormones and cognition demand ongoing rehab beyond 90 days—and how progress can continue.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.